Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03126916
Title Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Children's Oncology Group
Indications

neuroblastoma

nodular ganglioneuroblastoma

Therapies

Doxorubicin

131I-MIBG

Sargramostim

Etoposide

Melphalan

Busulfan

Isotretinoin

Vincristine Sulfate

Cisplatin

Cyclophosphamide

Thiotepa

Dexrazoxane

Lorlatinib

Carboplatin

Aldesleukin

Topotecan

Dinutuximab

Age Groups: adult | child
Covered Countries USA | CAN


No variant requirements are available.